Literature DB >> 12033767

Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.

Alexandra Eichten1, Matthew Westfall, Jennifer A Pietenpol, Karl Münger.   

Abstract

The p53 tumor suppressor is stabilized in cells expressing the human papillomavirus type 16 (HPV-16) E7 oncoprotein. In contrast, expression of the HPV-16 E6 protein inactivates p53 by targeting it for proteasomal degradation. Since p53 activation is associated with protein accumulation we investigated the biochemical mechanisms and biological consequences of p53 stabilization in HPV-16 E7-expressing cells. Transcriptional reporter assays, expression profiling studies using cDNA arrays, and immunoblot analyses of known p53 target genes suggest that p53 remains transcriptionally inert in E7-expressing cells. The stabilized p53 in E7-expressing cells is in a wild-type conformation and the same number of phospho-forms is present. Furthermore, E7 expression does not alter p53 localization or generally block nuclear export or proteasomal degradation of p53. Moreover, the stabilized p53 remains susceptible to mdm2-induced proteasome-mediated degradation, and exogenous transfected p53 is transcriptionally active in E7-expressing cells. Taken together, these results suggest that E7 can interfere with the normal turnover of p53 but that the resulting increase of p53 has no detectable transcriptional consequences on the p53 targets that we investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12033767     DOI: 10.1006/viro.2002.1375

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Authors:  Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 3.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

Review 4.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

Review 5.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

6.  Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.

Authors:  Nicole Brimer; Scott B Vande Pol
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

7.  Examination of the pRb-dependent and pRb-independent functions of E7 in vivo.

Authors:  Scott Balsitis; Fred Dick; Denis Lee; Linda Farrell; R Katherine Hyde; Anne E Griep; Nicholas Dyson; Paul F Lambert
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Roles of the PDZ domain-binding motif of the human papillomavirus type 16 E6 on the immortalization and differentiation of primary human foreskin keratinocytes.

Authors:  Moonju Choi; Sungjin Lee; Taekyu Choi; Choongho Lee
Journal:  Virus Genes       Date:  2013-11-29       Impact factor: 2.332

9.  Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation.

Authors:  Christy Hebner; Melanie Beglin; Laimonis A Laimins
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

10.  Role of WDHD1 in Human Papillomavirus-Mediated Oncogenesis Identified by Transcriptional Profiling of E7-Expressing Cells.

Authors:  Yunying Zhou; Qishu Zhang; Ge Gao; Xiaoli Zhang; Yafei Liu; Shoudao Yuan; Xiaowei Wang; Jason J Chen
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.